At Perito Urology, our mission doesn’t end when the surgery is over. We are committed to ongoing research and education, constantly asking how we can make procedures safer, more effective, and more durable for our patients.
This past month, Dr. Paul Perito and Dr. Alfredo Suarez-Sarmiento Jr., working alongside an incredible network of colleagues from around the globe, contributed to three major peer-reviewed publications in the field of prosthetic urology. These studies represent both cutting-edge innovation and candid acknowledgment of where challenges remain.
Here’s what we learned.
1. Prior Radiation Therapy is Associated with Increased Risk of Intraoperative Complications in Patients Undergoing Primary Inflatable Penile Prosthesis Placement: Results from a Large Multi-Institutional Collaborative
Dalimov Z, Ivan SJ, Barham DW, Hammad M, Miller J, Andrianne R, Burnett AL, Gross K, Hatzichristodoulou G, Hotaling J, Hsieh TC, Jenkins LC, Jones JM, Lentz A, Modgil V, Osmonov D, Park SH, Pearce I, Perito P, Sadeghi-Nejad H, Sempels M, Suarez-Sarmiento A Jr, van Renterghem K, Warner JN, Ziegelmann M, Yafi FA, Gross MS, Simhan J, on behalf of the PUMP collaborators. The Journal of Sexual Medicine. 2025.
This large multi-center PUMP (Prosthetic Urology Multi-Institutional Partnership) study found that men with prior pelvic radiation therapy had significantly higher rates of intraoperative complications during primary inflatable penile prosthesis (IPP) surgery:
- Complication rate: 4.3% in irradiated vs. 0.9% in non-irradiated patients (p = 0.032)
- Distal crossover events: 1.9% vs. 0% (p = 0.044)
- Independent risk factors: prior radiation (OR ≈ 5.95) and diabetes (OR ≈ 9.09)
Takeaway: Surgical planning must be more meticulous for these patients, with heightened awareness of potential complications.
2. Mechanical Failure of Inflatable Penile Prostheses: A 2025 Snapshot and Historical Context
Wilson SK, Mulcahy JJ, Köhler T, Perito P, Albayrak AT, Suarez Sarmiento A Jr. International Journal of Impotence Research. August 2025.
This paper combined contemporary device performance data with historical trends, offering a clear view of where today’s IPPs stand in terms of mechanical reliability.
While overall performance remains strong, one uncomfortable truth emerged from recent MAUDE (Manufacturer and User Facility Device Experience) database data:
- From January–May 2025, Coloplast devices accounted for 55.7% of adverse-event removals, a higher proportion than Boston Scientific.
- Tubing fractures continue to appear more frequently in some Coloplast models than in AMS 700® devices.
Takeaway: This isn’t about pointing fingers—it’s about pushing for engineering improvements and surgical technique refinements so that all devices can reach the highest durability standards. We use a multitude of solutions – they all have their benefits.
3. Perioperative Antimicrobial Strategies in IPP Surgery: Associations Between Antifungals, Oral Antibiotics, and IV Antibiotic Duration, and Infection Outcomes
The Journal of Urology. August 2025.
Infection prevention is central to successful IPP outcomes. This study analyzed how different antimicrobial regimens affected post-operative infection rates.
Key findings:
- Intravenous antifungals significantly lowered infection risk (OR = 0.22, p < 0.001).
- Extended IV antibiotic courses and oral antibiotics before or after surgery offered no additional benefit.
Takeaway: Less can be more—antimicrobial stewardship should prioritize interventions proven to reduce infection without unnecessary drug exposure.
Why These Studies Matter
Collectively, these publications highlight three pillars of better patient care:
- Risk recognition: Tailoring surgical plans for higher-risk patients.
- Device performance transparency: Acknowledging strengths and weaknesses to improve outcomes.
- Evidence-based infection prevention: Focusing resources where they matter most.
At Perito Urology, we believe progress comes from both celebrating advancements and confronting challenges head-on. These three publications represent exactly that: a collaborative push to make prosthetic urology safer, more durable, and more patient-focused.
We thank our global partners in these studies—and most of all, we thank our patients for trusting us as we work to make every outcome better than the last.